Rhumbline Advisers Affimed N.V. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	SELL	$0.57 - $1.08 $101,440 - $192,202	-177,965 Reduced 97.3%	4,940 $2,000
Q1 2023 May 11, 2023	BUY	$0.66 - $1.29 $3,898 - $7,620	5,907 Added 3.34%	182,905 $136,000
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $3,338 - $7,435	3,035 Added 1.74%	176,998 $219,000
Q3 2022 Nov 10, 2022	BUY	$1.96 - $3.32 $18,610 - $31,523	9,495 Added 5.77%	173,963 $358,000
Q2 2022 Aug 11, 2022	BUY	$2.27 - $4.86 $110,530 - $236,643	48,692 Added 42.06%	164,468 $456,000
Q1 2022 May 12, 2022	SELL	$3.69 - $5.65 $217 - $333	-59 Reduced 0.05%	115,776 $506,000
Q4 2021 Feb 10, 2022	SELL	$5.37 - $7.07 $3,044 - $4,008	-567 Reduced 0.49%	115,835 $639,000
Q3 2021 Nov 12, 2021	BUY	$5.54 - $7.51 $26,835 - $36,378	4,844 Added 4.34%	116,402 $719,000
Q2 2021 Aug 05, 2021	BUY	$7.78 - $11.4 $79,822 - $116,964	10,260 Added 10.13%	111,558 $948,000
Q1 2021 May 06, 2021	BUY	$5.12 - $8.48 $107,233 - $177,605	20,944 Added 26.06%	101,298 $801,000
Q4 2020 Feb 10, 2021	BUY	$3.16 - $7.03 $30,433 - $67,705	9,631 Added 13.62%	80,354 $468,000
Q3 2020 Nov 12, 2020	SELL	$3.26 - $4.73 $34,490 - $50,043	-10,580 Reduced 13.01%	70,723 $240,000
Q2 2020 Aug 13, 2020	BUY	$1.58 - $4.63 $34,290 - $100,484	21,703 Added 36.41%	81,303 $375,000
Q1 2020 May 06, 2020	BUY	$1.44 - $3.02 $5,868 - $12,306	4,075 Added 7.34%	59,600 $94,000
Q4 2019 Feb 05, 2020	BUY	$2.25 - $3.07 $10,755 - $14,674	4,780 Added 9.42%	55,525 $152,000
Q3 2019 Oct 23, 2019	BUY	$2.67 - $3.65 $9,035 - $12,351	3,384 Added 7.15%	50,745 $149,000
Q2 2019 Aug 14, 2019	BUY	$2.6 - $4.21 $123,138 - $199,389	47,361 New	47,361 $136,000

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account